Neomera BioLab
Neomera BioLab is a Stanford-rooted biotech startup at MBC BioLabs in San Carlos, CA, combining wet-lab biology with proprietary AI/ML (its ORBIT generative AI model for biologics) to drug hard membrane-protein targets such as GPCRs and ion channels.
About
Neomera BioLab is a Stanford-rooted biotech startup at MBC BioLabs in San Carlos, CA, combining wet-lab biology with proprietary AI/ML (its ORBIT generative AI model for biologics) to drug hard membrane-protein targets such as GPCRs and ion channels. Lead programs are peptide NaV1.8/NaV1.9 inhibitors for non-opioid chronic pain and modulators for depression and addiction relapse.
Capital graph
Founders / team· 2
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Neomera BioLab
Neomera BioLab is a Stanford-rooted biotech startup at MBC BioLabs in San Carlos, CA, combining wet-lab biology with proprietary AI/ML (its ORBIT generative AI model for biologics) to drug hard membrane-protein targets such as GPCRs and ion channels. Lead programs are peptide NaV1.8/NaV1.9 inhibitors for non-opioid chronic pain and modulators for depression and addiction relapse.
—
United States
BusinessLatest roundTotal raisedDate- Kekulai
Automates end-to-end small-molecule drug discovery with AI agent platform Allchymie, focusing on lead compound screening for "undruggable" autoimmune/inflammatory targets.
— - Onava
Onava is an AI-native biotech company in San Carlos, California, building an agentic, lab-in-the-loop antibody discovery platform that couples generative AI and ML-driven protein engineering with proprietary high-throughput functional assays to design potent, developable therapeutic antibodies against hard targets.
— - RyboDyn
AI-driven sequencing and discovery platform decoding the "dark proteome" to find cancer-specific cryptic targets in patient tumors that conventional methods miss, for first-in-class cancer immunotherapies
Seed · $14M · 2026-03
$14M
China
BusinessLatest roundTotal raisedDate- Nutshell Therapeutics
AI and physics-based computation for allosteric small-molecule drug discovery against hard-to-drug targets such as transcription factors
Series C · 2026-09
— - NeuShen Therapeutics
Novel drugs for CNS psychiatric and neurological disorders, with the NeuChime small-molecule discovery platform and NeuGem AAV gene therapy platform; lead programs include NS-136 (M4 positive allosteric modulator) and NS-041 (KCNQ2/3 activator)
Series B · 2026-09
— - AIPher
AI-native drug discovery: proprietary drug foundation models and AI agent engine for early discovery of novel small-molecule, peptide and other drugs
Angel · 2026-09
—
Europe
BusinessLatest roundTotal raisedDate- Isomorphic Labs
AI-driven drug design platform (IsoDDE engine): uses AlphaFold-based technology to predict protein structures and design new drug molecules; builds its own therapeutic pipeline and conducts joint R&D with large pharmaceutical companies
Series B · $2.7B · 2026-05
$2.7B - Turbine
Uses AI to simulate biological experiments, accelerating drug discovery and translational research
Series B · $25M · 2026-03
$25M - Helical
Turns biology AI foundation models into reproducible drug discovery workflows for pharma teams
Seed · $20M · 2026-04
$20M
Other / unspecified
BusinessLatest roundTotal raisedDate- Miles Wang 新公司
Develops AI models for drug discovery
— - Galux
AI plus physics-based protein/antibody design platform (GaluxDesign) for drug discovery
Series B · $58M · 2026-02
$58M - Halmos Labs
AI-driven automated R&D systems for biotech and pharma that simulate experimental outcomes before wet-lab work and recommend the experiments that most reduce uncertainty
—
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 22 in Silicon Valley
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.